Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data

Abstract : BACKGROUND: Observational studies suggested that androgen deprivation therapy (ADT) is associated with an increased cardiovascular (CV) risk. They all compared ADT-treated cancer patients to non-treated patients or non-cancer subjects. Our aim was to evaluate whether CV risk differs by type of ADT. METHODS: Through nationwide population-based claims reimbursement database linked to hospital discharge database, we identified adult men with prostate cancer who initiated ADT (gonadotrophin releasing hormone [GnRH] agonist or antagonist, antiandrogen [AA], combined androgen blockade [CAB]) or had orchiectomy (OT) between 1st July, 2010, and the 31st December, 2011, and followed them up to 31st December, 2013. The main analysis followed an 'on-treatment' approach that censored all patients at the time of first therapeutic modification; it used Cox regression analysis to estimate hazard ratios (HRs) for hospitalisations for ischaemic events (myocardial infarction or ischaemic stroke, whichever came first), adjusted on age, baseline co-morbidities and taking into account death as a competing risk. RESULTS: Among the 35,118 new ADT users, 71% received GnRH agonist (reference group), 12% CAB, 13% AA, 3.6% GnRH antagonist and 0.6% had OT. CAB was associated with an increased risk (adjusted HR [95% confidence interval _CI_], 1.6 [1.3-2.0]) and AA with a decreased risk (adjusted HR [95% CI], 0.6 [0.4-0.9]) of ischaemic events when compared to GnRH agonist. No significant association was found with GnRH antagonist (adjusted HR [95% CI], 1.2 (0.7-2.1)). CONCLUSION: CV risk appeared different across ADT modalities. The probability of a clinically meaningful difference when comparing GnRH antagonists to agonists appears rather low. In a context where better overall and cancer specific survival without worsening quality of life is a challenge for clinicians, a potential heterogeneity in CV morbidity becomes crucial when choosing an ADT.
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01519865
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, May 9, 2017 - 2:21:50 PM
Last modification on : Wednesday, May 16, 2018 - 11:24:11 AM

Identifiers

Citation

Lucie-Marie Scailteux, Sébastien Vincendeau, Frédéric Balusson, Christophe Leclercq, André Happe, et al.. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. European Journal of Cancer, 2017, 77, pp.99-108. ⟨10.1016/j.ejca.2017.03.002⟩. ⟨hal-01519865⟩

Share

Metrics

Record views

134